Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res
about
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyEfficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDSEffectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed ViremiaTherapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical TrialsHIV integrase inhibitors: a new era in the treatment of HIV.Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.Inflammation, Immune Activation, and Antiretroviral Therapy in HIVImpact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted ProteMeta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment RegimensModifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical TrialsAntiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA PanelSwitch strategies in antiretroviral therapy regimens.The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.Switching antiretroviral regimes for the treatment of HIV: safety implications.Elvitegravir for the treatment of HIV.Single-Tablet Regimens for the Treatment of HIV-1 Infection.Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice.Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials.Elvitegravir concentrations in seminal plasma in HIV-1-infected men.Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.IAPAC Guidelines for Optimizing the HIV Care Continuum for Adults and Adolescents.HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis.Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD).A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes.Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.
P2860
Q26771182-C878E105-8502-4DA4-9D39-A0D44CE5BD53Q26783253-8B8147BB-1EEA-4536-9EDF-DE8E92F95B2CQ28548630-3A4C75AD-4C2A-4887-A85A-778BB1C37C58Q28553571-804FB11E-7EBE-4FDF-9560-02D040B32A87Q30956943-BA2F0786-294C-4417-892B-D3A3805D8EB0Q33817410-02F2A783-684C-44DC-8A3C-D5E6509F0DE4Q33912595-49DE602E-A922-4D91-8B36-4AB0D3D5436FQ35567828-E8FD8502-A843-413D-94A4-CB7CB528358BQ36073609-1EAB9019-0083-4D53-8ABA-8E03AE5010A0Q36206941-A8D3ACDB-2E04-4630-BE85-9C1D3EA5F7CDQ36426953-568492AA-E8F1-44E4-A6A1-C4E454B99E68Q37221125-498E9EAF-5F20-40FD-B5C0-D74FCD4F0DF5Q37234729-A02BEAF6-3BD0-441D-8844-8371F6354A63Q38235295-3B7691EF-E9FD-4A80-9903-20361FAD2FA6Q38305617-5A051126-40F2-4C2E-840E-9398DF4EE84CQ38570500-AF97C804-82C2-4E70-BC68-974994374E1FQ38719799-938B3576-6796-4552-8ED0-84CA0756F324Q38723259-2752E5BA-030D-4E4A-A88E-48642030FD57Q38813848-ABE8DD90-78D7-4838-B69C-9BB8CFD158F8Q38879406-4CFEA3D0-DBA2-497C-8713-82E821C347E0Q38987327-521574C7-8BB9-497D-986F-099901DA8B52Q39022885-1D02454B-FBA6-489A-912C-FC0E8DE14339Q39097668-667E6245-8654-4238-9508-0A579E61EFD4Q40100018-1B24BCF9-3FCA-4C33-BF4B-E3EF7B832A2BQ40143100-FEB92E58-D773-4BF9-A3F4-ABB222D73C78Q40145206-7982BAAB-2518-42D8-9815-53DEFA54BA6CQ40194507-2C4E5E42-9071-4B54-A4E4-2D809DBF1ED5Q40437474-991464C8-C201-4396-8E1D-81D89CE2483BQ40516279-76E3E861-AFE8-4B3D-8CBE-EF177885409FQ40593858-8D5568F4-46A1-407C-958D-6EAD6AB8D193Q40735151-E4CFA076-0F55-455F-A13E-CE22B5786B56Q40925906-0A579D7B-B44C-4A68-BEB1-8793FB24FE10Q41465991-6E2868B1-4A25-4313-A86D-90C8DDDD194BQ41661353-14907BBA-90DA-4ABF-9DE0-D827A23D4133Q45961010-59C34C1F-0979-44EF-952D-FCD27255FCCDQ47145824-0B2FA45B-5CDB-42AF-929A-02AAC07B3C40Q47164735-4D106D5A-D148-4F06-98B2-0233F4F5A351Q47305467-5A78FEF2-BB0E-4C15-96F3-C312739D7380Q47321307-812868D8-DF0E-416B-B102-7CE9C953BEC0Q55280381-1EC45CCB-BAD0-4553-9BF3-29C6A52A3F13
P2860
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Simplification to coformulated ...... HIV (STRATEGY-PI): 48 week res
@en
Simplification to coformulated ...... HIV (STRATEGY-PI): 48 week res
@nl
type
label
Simplification to coformulated ...... HIV (STRATEGY-PI): 48 week res
@en
Simplification to coformulated ...... HIV (STRATEGY-PI): 48 week res
@nl
prefLabel
Simplification to coformulated ...... HIV (STRATEGY-PI): 48 week res
@en
Simplification to coformulated ...... HIV (STRATEGY-PI): 48 week res
@nl
P2093
P1476
Simplification to coformulated ...... HIV (STRATEGY-PI): 48 week res
@en
P2093
David Piontkowsky
Gilles Pialoux
Giovanni Di Perri
Jacques Reynes
Joseph Gathe
Kirsten White
Ramin Ebrahimi
Thai Nguyen
P304
P356
10.1016/S1473-3099(14)70782-0
P577
2014-06-05T00:00:00Z